Immunotherapy with low dose interleukin-2 after cytoreductive chemotherapy for patients with hormone refractory metastatic prostate cancer: a phase I/II study.
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2007
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Nov 2007 Status changed from in progress to completed.
- 25 Sep 2006 New trial record.